Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
about
Aberrantly expressed microRNAs in the context of bladder tumorigenesisThe association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese populationSomatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.Overexpression of KLF13 and FGFR3 in oral cancer cells.A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Bladder cancer: a simple model becomes complex.FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.Clinical states model for biomarkers in bladder cancerFGFR3 has tumor suppressor properties in cells with epithelial phenotype.The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.Molecular determinants of tumor recurrence in the urinary bladder.Latest developments in imaging of bladder cancer.Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.Biology of FGFRL1, the fifth fibroblast growth factor receptor.Contemporary management of low-risk bladder cancer.Immunohistochemical biomarkers for bladder cancer prognosis.Biomolecular predictors of urothelial cancer behavior and treatment outcomes.Urinary protein biomarkers of cancer.Predictive markers in bladder cancer: do we have molecular markers ready for clinical use?Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.Noninvasive approaches for detecting and monitoring bladder cancer.SLC14A1: a novel target for human urothelial cancer.FGFR3 mutations in prostate cancer: association with low-grade tumors.The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma.Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
P2860
Q26744152-56724607-C627-4AB0-9C44-2E3AE0C7CFC3Q28392404-10426397-0440-4322-A020-42B757A926FBQ33891125-E865969C-97ED-4434-A149-27A279C62DEEQ33928136-422C2D13-C2B5-4522-8A60-AE74ADDC0D03Q34524813-332815B7-EB3A-41DB-A5A8-03B9C1A4BDA9Q34611953-0E498B7B-EEAD-469D-8536-494DA1740E2DQ35151119-457774F9-DEC6-42C6-9A21-BFB64F2877D8Q36061127-09B38A14-4DB2-4B5A-B4FA-03EA31D1A0CCQ36108115-0178AC8C-96B2-46D2-BF5F-75163EE5E9CBQ36882005-EFE24A29-58E3-4662-BA8A-C3D78AE6A814Q36995765-8604D36C-A26E-4D74-955D-28E7B244EB0DQ37113037-0A3BA796-3CA1-4D49-8D20-C30D4343C7CCQ37295512-B3B65C93-481F-4A99-93F4-7D740E520855Q37363038-C5047F28-73FB-45A0-94E2-9C9A84D9E702Q37575626-C0157F33-0195-4D4E-95F1-EE08F8982500Q37765587-F0AB94B1-B915-452F-B48A-4FE48B195CC6Q37770783-108099B8-9F1F-4BB6-A43A-CEA1BBB6340DQ37809766-2183B863-7EBE-4620-9639-37EE11C31C73Q37828064-3B979E51-039C-436F-A00C-7682D31A5AC4Q37902697-173D148D-1240-4456-88B3-90DD3DF9C2A4Q37987066-7545D846-25AB-47BF-947D-006A530165DDQ38089063-DA8921B5-43CC-485F-B0D1-389F896EFC38Q38230912-335B36E0-ABAD-44C6-8F3C-D3D506249FABQ38285703-B0AD5BA4-34AA-4487-8585-08B0456DA75FQ38286089-3210411A-95D9-4547-8DE1-B161644EF477Q39356231-1132B9F7-3317-4455-8F01-520A2678C6FCQ47984250-CBAAA1D7-66BD-4B87-8E92-611A266800E1Q50182629-A3E58717-85DE-42B2-B91B-A4252E0DE9FEQ54188080-CF423F74-DF77-4E0E-8F22-F30F46BB2F30Q54399355-9A48322D-599E-42DE-9AF7-B836136DC05BQ54647137-39F10469-7E51-4E30-A099-16CC360487A9Q54651233-BBFD57DE-7AD4-4B14-B77B-67C44FEDCE25
P2860
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en-gb
type
label
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en-gb
prefLabel
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en-gb
P2860
P1476
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
@en
P2860
P2888
P304
P356
10.1007/S00345-007-0213-4
P577
2007-10-03T00:00:00Z